Prescription medication · Anti-IL-17 Receptor Monoclonal Antibody
brodalumab
Also sold as Siliq. Siliq treats moderate to severe plaque psoriasis.
Data updated 2026-05-15
- 1,890
- FDA reportsRarely reported
- 2
- InteractionsFew interactions
- Rx
- Availability
What the data shows
brodalumab (Siliq) is a prescription Anti-IL-17 Receptor Monoclonal Antibody, among the least-reported drugs the FDA tracks (1,890 FDA reports), with 2 documented drug interactions.
Reporting volume reflects how widely a drug is used and studied, not how dangerous it is, a FAERS report documents a temporal association, never proof of cause.
brodalumab (Siliq) is a prescription Anti-IL-17 Receptor Monoclonal Antibody. Siliq treats moderate to severe plaque psoriasis.
Siliq is a medicine used to treat moderate to severe plaque psoriasis. It is for adults who can use systemic therapy or phototherapy and have not responded well to other treatments.
Verify with FDA → · CMS NADAC pricing →
What it does
Siliq treats moderate to severe plaque psoriasis.
Common side effects
Joint pain, Headache, Feeling tired
Key warnings
Siliq may cause suicidal thoughts and behavior.
The sections below are summarized in plain English from brodalumab's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.
How It Works
Siliq blocks a protein called interleukin-17 receptor A (IL-17RA). This protein is involved in causing inflammation in psoriasis. By blocking it, Siliq helps reduce the symptoms of psoriasis.
Side Effects (from patient reports)
Based on 1,890 FDA adverse event reports.
Most-reported reactions
Adverse reactions in FAERS for brodalumab, by number of reports
- Psoriasis
Psoriasis
471 reports
- Arthralgia 181
Arthralgia
181 reports
- Fatigue 163
Fatigue
163 reports
- Psoriatic Arthropathy 156
Psoriatic Arthropathy
156 reports
- Disease Recurrence 129
Disease Recurrence
129 reports
- Headache 126
Headache
126 reports
- Therapy Interrupted 124
Therapy Interrupted
124 reports
- Inappropriate Schedule Of Product Administration 115
Inappropriate Schedule Of Product Administration
115 reports
- Diarrhoea 91
Diarrhoea
91 reports
- Covid-19 87
Covid-19
87 reports
What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.
Reports over time
Adverse-event reports filed for brodalumab each year to the FDA Adverse Event Reporting System (FAERS).
Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.
Where brodalumab sits
brodalumab has more FDA adverse-event reports than 12% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.
Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is brodalumab; the line is the median (50th percentile).
FDA Adverse Event Report Analysis
Detailed analysis of 1,890 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2013–2025.
Total Reports
1,890
Reports Mentioning Death
133
7.0% of reports — not proof of cause
Hospitalization Reports
535
Top Indication
Psoriasis
Gender Distribution
Age Distribution
Most Reported Adverse Reactions (FAERS)
| # | Reaction | Reports |
|---|---|---|
| 1 | PSORIASIS | 471 |
| 3 | ARTHRALGIA | 181 |
| 4 | FATIGUE | 163 |
| 5 | PSORIATIC ARTHROPATHY | 156 |
| 8 | DISEASE RECURRENCE | 129 |
| 9 | HEADACHE | 126 |
| 10 | THERAPY INTERRUPTED | 124 |
| 12 | INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION | 115 |
| 13 | DIARRHOEA | 91 |
| 14 | COVID-19 | 87 |
| 15 | PAIN IN EXTREMITY | 87 |
| 16 | THERAPY CESSATION | 85 |
| 17 | CONDITION AGGRAVATED | 80 |
| 18 | PRURITUS | 77 |
| 19 | PATIENT DISSATISFACTION WITH TREATMENT | 74 |
Reactions in Death Reports
Reactions in Hospitalization Reports
Source: FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation
Serious Warnings
Siliq may cause suicidal thoughts and behavior. Tell your doctor if you have a history of depression or suicidal thoughts. If you have new or worsening suicidal thoughts or depression, get medical help right away. Siliq is only available through a special program because of this risk.
Known Drug Interactions
Therefore, upon initiation or discontinuation of SILIQ in patients who are receiving concomitant drugs which are CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for effect (e.g., for warfarin) or drug concentration (e.g., for cyclosporine) and consider dosage modification of the CYP450 substrate [see Clinical Pharmacology ( 12.3 )].
Mechanism: Brodalumab can change how your liver enzymes break down other medicines like warfarin. This can cause the amount of warfarin in your body to go up or down.
Therefore, upon initiation or discontinuation of SILIQ in patients who are receiving concomitant drugs which are CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for effect (e.g., for warfarin) or drug concentration (e.g., for cyclosporine) and consider dosage modification of the CYP450 substrate [see Clinical Pharmacology ( 12.3 )].
Mechanism: Brodalumab may affect the liver enzymes that process cyclosporine, which can lead to changes in the amount of medicine in your blood.
This is a plain-language summary of FDA-label interaction records and does not provide individual medication-combination directions.
Common Questions
What should I do before starting Siliq?
Can Siliq cause allergic reactions?
What if I get an infection while taking Siliq?
Can I get vaccines while using Siliq?
What if I have new or worsening depression while on Siliq?
How long can Siliq be stored at room temperature?
What does Siliq look like?
How is Siliq given?
What if Siliq doesn't work after a few months?
Can Siliq affect other medicines I'm taking?
What are the common side effects of brodalumab?
Does brodalumab interact with other medications?
What drug class is brodalumab?
What pregnancy or breastfeeding source fields are listed for brodalumab?
Related Medications in Anti-IL-17 Receptor Monoclonal Antibody
Other drugs grouped near brodalumab - same-class peers and common alternatives.
adapalene
Differin
Compare with brodalumab →
apremilast
Otezla
Apremilast (Otezla/Otezla XR) is a medicine that can help adults and children manage psoriatic arthritis and psoriasis.
Compare with brodalumab →
azelaic acid
Finacea, Azelex
Azelaic acid gel is a topical medicine that helps treat rosacea.
Compare with brodalumab →
benzoyl peroxide
Benzac, PanOxyl
Benzoyl peroxide is a topical medicine that fights germs on your skin.
Compare with brodalumab →
betamethasone
Diprosone, Luxiq
Betamethasone dipropionate cream is a strong steroid medicine used on the skin.
Compare with brodalumab →
Compare beyond drug class
Nationwide peers by FAERS volume & death-report share
Two PlainMeds-derived comparison paths for brodalumab: nearest FDA FAERS report volume and nearest death-report share among drugs with at least 1,000 logged reports, excluding same-class neighbors listed above. Counts reflect reporting volume, not proven individual harm.
Similar FAERS report volume
Nearest drugs by total FAERS reports. This record: 1,890.
Similar death-report share
Nearest drugs by FAERS death-report share. This record: 7.04%.
- cholestyramine Δ 0.01 pts · 11,539 reports · Bile Acid Sequestrant 7.03%death share
- hydrochlorothiazide Δ 0.01 pts · 140,497 reports · Thiazide Diuretic 7.03%death share
- mupirocin Δ 0.02 pts · 12,758 reports · Topical Antibiotic 7.02%death share
- umeclidinium Δ 0.06 pts · 8,530 reports · Long-Acting Muscarinic Antagonist (LAMA) 7.09%death share
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
FDA bioequivalence and label-record context for narrow therapeutic index medicines
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on brodalumab
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for brodalumab
The FDA label for brodalumab (sold under brand names such as Siliq) classifies it as a prescription-only medication in the Anti-IL-17 Receptor Monoclonal Antibody class. Siliq treats moderate to severe plaque psoriasis. Official labeling lists 11 commonly reported side effects, including Joint pain, Headache, Feeling tired.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 1,890 voluntary reports. The database also lists 2 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated minor severity. Acquisition-cost data is surveyed weekly by CMS and updated as manufacturers report changes.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.
Last updated: February 11, 2026
PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages